Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published

Market Focus

Aug 20

On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical data disclosure.

On the news front, the company's wholly-owned subsidiary Leads Biolabs Inc. received written notice from Oblenio Bio, Inc. formally exercising its exclusive option to retain the global development, manufacturing, and commercialization license for LBL-051. Under the agreement signed in November 2024, Oblenio will pay a one-time, non-refundable and non-creditable fee of US$10 million. The company views the option exercise as a significant collaboration milestone that lays the groundwork for LBL-051's global clinical development and commercialization.

Simultaneously, the company announced that the Phase II clinical study abstract for its core product Welixin (opamtistomig, PD-L1/4-1BB bispecific antibody, LBL-024) as first-line treatment for NSCLC was published on the WCLC official website, adding further visibility to its pipeline progress ahead of the upcoming mid-term results review scheduled for August 31.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1143205687"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143205687\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143205687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143205687","market":"hk","top_or_hot":-1,"title":"Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","media":"Market Focus","content":"<p><p>On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical data disclosure.</p><p>On the news front, the company's wholly-owned subsidiary Leads Biolabs Inc. received written notice from Oblenio Bio, Inc. formally exercising its exclusive option to retain the global development, manufacturing, and commercialization license for LBL-051. Under the agreement signed in November 2024, Oblenio will pay a one-time, non-refundable and non-creditable fee of US$10 million. The company views the option exercise as a significant collaboration milestone that lays the groundwork for LBL-051's global clinical development and commercialization.</p><p>Simultaneously, the company announced that the Phase II clinical study abstract for its core product Welixin (opamtistomig, PD-L1/4-1BB bispecific antibody, LBL-024) as first-line treatment for NSCLC was published on the WCLC official website, adding further visibility to its pipeline progress ahead of the upcoming mid-term results review scheduled for August 31.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 10:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical data disclosure.</p><p>On the news front, the company's wholly-owned subsidiary Leads Biolabs Inc. received written notice from Oblenio Bio, Inc. formally exercising its exclusive option to retain the global development, manufacturing, and commercialization license for LBL-051. Under the agreement signed in November 2024, Oblenio will pay a one-time, non-refundable and non-creditable fee of US$10 million. The company views the option exercise as a significant collaboration milestone that lays the groundwork for LBL-051's global clinical development and commercialization.</p><p>Simultaneously, the company announced that the Phase II clinical study abstract for its core product Welixin (opamtistomig, PD-L1/4-1BB bispecific antibody, LBL-024) as first-line treatment for NSCLC was published on the WCLC official website, adding further visibility to its pipeline progress ahead of the upcoming mid-term results review scheduled for August 31.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1143205687","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143205687","pubTimestamp":1787194735,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"走势警报|随着 WCLC 肺癌数据公布，BIOLABS-B 领先优势在常规交易中上涨 5.25%，Oblenio 行使 LBL-051 全球许可期权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical data disclosure.On the news front, the company's wholly-owned subsidiary Leads Biolabs Inc. received written notice from Oblenio Bio, Inc. formally exercising its exclusive option to retain the global development, manufacturing, and commercialization license for LBL-051. Under the agreement signed in November 2024, Oblenio will pay a one-time, non-refundable and non-creditable fee of US$10 million. The company views the option exercise as a significant collaboration milestone that lays the groundwork for LBL-051's global clinical development and commercialization.Simultaneously, the company announced that the Phase II clinical study abstract for its core product Welixin (opamtistomig, PD-L1/4-1BB bispecific antibody, LBL-024) as first-line treatment for NSCLC was published on the WCLC official website, adding further visibility to its pipeline progress ahead of the upcoming mid-term results review scheduled for August 31.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}